Gene Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Gene Symbol APC
Synonyms BTPS2 | DESMD | DP2 | DP2.5 | DP3 | GS | PPP1R46
Gene Description APC, adenomatous polyposis coli, is a tumor suppressor (PMID: 30562755) and multi-domain protein regulating numerous cellular functions through interaction with beta-catenin and subsequent inhibition of Wnt signalling (PMID: 10959075). APC germline mutations are associated with familial adenomatous polyposis (PMID: 30562755) and somatic mutations with colon, endometrial, NSCLC, and breast cancers (PMID: 27283171).
ACMG Incidental List v3.0:
Yes, Familial adenomatous polyposis (PMID: 34012068)
NCBI Gene ID Chromosome Map Location Canonical Transcript Gene Role
324 5 5q22.2 NM_000038 Tumor suppressor (PMID: 30606230)

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
APC inact mut colon cancer sensitive Sirolimus Preclinical Actionable In preclinical trials, Sirolimus (rapamycin) was shown effective in reducing tumors in mouse models of familial adenomatous polyposis and colon cancer with APC deficient tumors (PMID: 18768809, PMID: 20080688). 18768809 20080688
APC inact mut colon cancer sensitive Vinorelbine Preclinical Actionable In preclinical studies, cells deficient in Apc protein had increased sensitivity to Navelbine (vinorelbine) compared to wild-type cells, and Navelbine (vinorelbine) treament decreased adenoma size in an Apc-deficient mouse model (PMID: 22399804). 22399804
APC inact mut colon cancer sensitive Vandetanib Preclinical Actionable In a preclinical study, Caprelsa (vandetanib) reduced the number of dextran sodium sulfate-induced tumors in an APC-deficient mouse model for colon cancer (PMID: 20811697). 20811697
APC inact mut colorectal cancer sensitive Celecoxib + Erlotinib Preclinical - Cell line xenograft Actionable In a preclinical study, Celebra (celecoxib), in combination with Tarceva (erlotinib), demonstrated efficacy in reducing tumor number and volume in APC inactivating mutant mice and in human colorectal cancer cell line xenograft models (PMID: 17909047). 17909047
APC inact mut colorectal cancer sensitive Celecoxib Preclinical Actionable In a preclinical study, APC inactivating mutant mouse models of colon cancer had reduced polyp formation after treatment with Celebra (celecoxib) (PMID: 17909047). 17909047
APC inact mut colorectal cancer sensitive Sulindac Preclinical Actionable In a preclinical study, colorectal cancer mouse models carrying APC inactivating mutations had reduced intestinal tumor burden after treatment with Clinoril (sulindac) (PMID: 19755659). 19755659
APC inact mut colorectal cancer sensitive Erlotinib + Ibuprofen Preclinical - Cell line xenograft Actionable In a preclinical study, ibuprofen, in combination with Tarceva (erlotinib), demonstrated efficacy in reducing tumor number and volume in APC inactivating mutant mice and in cell line xenograft models of colorectal cancer (PMID: 17909047). 17909047
APC inact mut colorectal cancer sensitive Dasatinib Preclinical Actionable In a preclinical study, the combination of Sprycel (dasatinib) and curcumin inhibited tumor growth in a mouse model of colorectal cancer harboring an Apc mutation (PMID: 20473900). 20473900
APC inact mut colon cancer sensitive CGP049090 Preclinical Actionable In a preclinical study, CGP049090 inhibited proliferation of a colorectal cancer cell line harboring an APC inactivating mutation in culture (PMID: 14749129). 14749129
APC inact mut colon cancer sensitive ICG-001 Preclinical Actionable In a preclinical study, ICG-001 decreased cell proliferation in colon cancer cell lines and in mouse models carrying APC inactivating mutations (PMID: 15314234). 15314234
APC inact mut colon cancer sensitive MF tricyclic Preclinical Actionable In a preclinical study, mouse models of colon cancer carrying an APC 716del mutation had reduced polyp formation after treatment with MF tricyclic (PMID: 23843721). 23843721
APC inact mut colon cancer sensitive PKF115-584 Preclinical Actionable In a preclinical study, PKF115-584 inhibited proliferation of colorectal cancer cell line harboring an APC inactivating mutation in culture (PMID: 14749129). 14749129
APC inact mut colon cancer sensitive StAx-35 Preclinical Actionable In a preclinical study, StAx-35 inhibited proliferation of colon cancer cell lines carrying APC deletions in culture (PMID: 23071338). 23071338
APC inact mut colorectal cancer sensitive XAV939 Preclinical Actionable In a preclinical study, XAV939 inhibited growth of colorectal cancer cells harboring APC inactivating mutations in culture (PMID: 19759537). 19759537
APC inact mut colon carcinoma sensitive FH535 Preclinical Actionable In a preclinical study, FH535 inhibited beta-catenin/TCF-dependent transactivation and demonstrated toxicity in colon carcinoma cells harboring an APC mutation in culture (PMID: 18347139). 18347139
APC inact mut colorectal cancer sensitive PKF118-310 Preclinical Actionable In a preclinical study, PKF118-310 inhibited proliferation of colorectal cancer cell line harboring an APC inactivating mutation in culture (PMID: 14749129). 14749129
APC inact mut colorectal cancer sensitive CCT036477 Preclinical Actionable In a preclinical study, CCT036477 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC inactivating mutations in culture (PMID: 20610623). 20610623
APC inact mut colorectal cancer sensitive CCT070535 Preclinical Actionable In a preclinical study, CCT070535 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC inactivating mutations in culture (PMID: 20610623). 20610623
APC inact mut colorectal cancer sensitive CCT031374 Preclinical Actionable In a preclinical study, CCT031374 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC inactivating mutations in culture (PMID: 20610623). 20610623
APC inact mut colon cancer sensitive iCRT-3 Preclinical Actionable In a preclinical study, iCRT-3 induced cell-cycle arrest and inhibited proliferation of colon cancer cells harboring APC inactivating mutations in culture (PMID: 21393571). 21393571
APC inact mut colorectal cancer sensitive NC043 Preclinical - Cell line xenograft Actionable In a preclinical study, NC043 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC truncation mutations in culture and in cell line xenograft models (PMID: 21321609). 21321609
APC inact mut colon cancer sensitive JW55 Preclinical Actionable In a preclinical study, JW55 inhibited proliferation of colorectal cancer cells with an APC truncation mutation in culture and decreased tumor development in a mouse model expressing a conditional APC truncation mutation (PMID: 22440753). 22440753
APC inact mut colorectal cancer sensitive Pyrvinium Preclinical Actionable In a preclinical study, Pyrvinium inhibited Wnt signaling and decreased viability of colon cancer cells harboring APC mutations in culture (PMID: 20890287). 20890287
APC inact mut colon cancer sensitive iCRT-5 Preclinical Actionable In a preclinical study, iCRT-5 induced cell-cycle arrest and inhibited proliferation of colon cancer cells harboring APC inactivating mutations in culture (PMID: 21393571). 21393571
APC inact mut colon cancer sensitive iCRT-14 Preclinical - Cell line xenograft Actionable In a preclinical study, iCRT-14 induced cell-cycle arrest and inhibited proliferation of colon cancer cells harboring APC inactivating mutations in culture and decreased initial tumor growth in APC-mutant colon cancer cell line xenograft models (PMID: 21393571). 21393571
APC inact mut colon cancer sensitive G007-LK Preclinical - Cell line xenograft Actionable In a preclinical study, G007-LK inhibited growth of APC-mutant colorectal cancer cell lines in culture and in xenograft models (PMID: 23539443). 23539443
APC inact mut colorectal cancer sensitive Niclosamide Preclinical Actionable In a preclinical study, Niclosamide inhibited proliferation of colorectal cancer cells harboring APC mutations in culture (PMID: 21531761). 21531761
APC Q1338* colorectal cancer sensitive JW67 Preclinical Actionable In a preclinical study, JW67 inhibited Wnt signaling and decreased proliferation of colorectal cancer cells harboring APC Q1338* in culture (PMID: 21199802). 21199802
APC Q1338* colorectal cancer sensitive JW74 Preclinical Actionable In a preclinical study, JW74 inhibited Wnt signaling and decreased growth of colorectal cancer cells harboring APC Q1338* in culture and in xenograft models (PMID: 21199802). 21199802
APC mutant colorectal cancer sensitive JW74 Preclinical Actionable In a preclinical study, JW74 reduced tumor formation and growth in a mouse model of colorectal cancer harboring an APC mutation (PMID: 21199802). 21199802
APC mutant colorectal cancer no benefit G-631 Preclinical - Cell line xenograft Actionable In a preclinical study, G-631 inhibited Wnt pathway signaling in colorectal cancer cell line xenograft models harboring an APC mutation, but demonstrated little anti-tumor activity and led to intestinal toxicity (PMID: 26692561). 26692561
APC wild-type CTNNB1 wild-type colon cancer predicted - sensitive Vantictumab Preclinical - Pdx Actionable In a preclinical study, Vantictumab (OMP-18R5) inhibited tumor growth in patient-derived xenograft models of colon cancer with wild-type CTNNB1 (beta-catenin) and APC (PMID: 22753465). 22753465
APC mutant colorectal cancer predicted - sensitive K-756 Preclinical Actionable In a preclinical study, K-756 inhibited Wnt signaling and reduced growth of 2/3 tested APC-mutant colorectal cancer cell lines in culture (PMID: 27196752). 27196752
APC wild-type colorectal cancer resistant TASIN-1 Preclinical - Cell line xenograft Actionable In a preclinical study, TASIN-1 did not inhibit survival of APC wild-type colorectal cancer cells in culture or in cell line xenograft models (PMID: 27798265). 27798265
APC inact mut colorectal cancer sensitive TASIN-1 Preclinical - Cell line xenograft Actionable In a preclinical study, TASIN-1 efficiently inhibited survival of colorectal cancer cell lines harboring APC truncation mutations in culture and in cell line xenograft models (PMID: 27798265). 27798265
APC E1309* colorectal cancer sensitive TASIN-1 Preclinical - Cell line xenograft Actionable In a preclinical study, TASIN-1 efficiently inhibited survival of colorectal cancer cells harboring APC E1309* in culture and in cell line xenograft models (PMID: 27798265). 27798265
APC E853* APC K1555* colorectal cancer sensitive TASIN-1 Preclinical - Cell line xenograft Actionable In a preclinical study, TASIN-1 efficiently inhibited survival of colorectal cancer cells harboring APC E853* and APC K1555* in culture and inhibited tumor growth in xenograft models (PMID: 27798265). 27798265
APC Q1131* APC Q1303* colorectal cancer sensitive TASIN-1 Preclinical - Cell culture Actionable In a preclinical study, TASIN-1 inhibited survival of colorectal cancer cells harboring APC Q1131* and APC Q1303* in culture (PMID: 27798265). 27798265
APC Q1338* colorectal cancer sensitive TASIN-1 Preclinical - Cell culture Actionable In a preclinical study, TASIN-1 inhibited survival of colorectal cancer cell lines harboring APC Q1338* in culture (PMID: 27798265). 27798265
APC L1488* colorectal cancer sensitive TASIN-1 Preclinical - Cell culture Actionable In a preclinical study, TASIN-1 inhibited survival of colorectal cancer cells harboring APC L1488* in culture (PMID: 27798265). 27798265
APC G1416* colorectal cancer sensitive TASIN-1 Preclinical - Cell culture Actionable In a preclinical study, TASIN-1 inhibited survival of colorectal cancer cell lines harboring APC G1416* in culture (PMID: 27798265). 27798265
APC inact mut PTEN inact mut colorectal cancer sensitive Dactolisib Preclinical Actionable In a preclinical study, BEZ235 inhibited PI3K/mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338). 26206338
APC inact mut PTEN inact mut colorectal cancer no benefit Binimetinib Preclinical Actionable In a preclinical study, Binimetinib (MEK162) reduced proliferation in tumors acutely but did not improve survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338). 26206338
APC inact mut PTEN inact mut colorectal cancer no benefit Binimetinib + Dactolisib Preclinical Actionable In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) did not improve survival compared to single agent in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338). 26206338
APC S811* colorectal cancer sensitive G007-LK Preclinical - Cell culture Actionable In a preclinical study, treatment with G007-LK decreased active beta-catenin levels and Tcf/LEF activity, and reduced growth of a colorectal cancer cell line harboring APC S811* in culture (PMID: 28179481). 28179481
APC S1197* APC S1278* colorectal cancer sensitive G007-LK Preclinical - Cell culture Actionable In a preclinical study, treatment with G007-LK decreased active beta-catenin levels and Tcf/LEF activity, and reduced growth of a colorectal cancer cell line harboring APC S1197* and APC S1278* in culture (PMID: 28179481). 28179481
APC L665* APC R1450* colorectal cancer resistant G007-LK Preclinical - Cell culture Actionable In a preclinical study, a colorectal cancer cell line harboring APC L665* and APC R1450* demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with G007-LK in culture (PMID: 28179481). 28179481
APC E853* APC T1556fs colorectal cancer resistant G007-LK Preclinical - Cell culture Actionable In a preclinical study, a colorectal cancer cell line harboring APC E853* and APC T1556fs (reported as APC T1556fs*3) demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with G007-LK in culture (PMID: 28179481). 28179481
APC N1819fs APC wild-type colorectal cancer resistant G007-LK Preclinical - Cell culture Actionable In a preclinical study, a colorectal cancer cell line harboring APC N1819fs (reported as N1819fs*7) and a wild-type copy of APC demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with G007-LK in culture (PMID: 28179481). 28179481
APC S811* colorectal cancer sensitive IWR-1 Preclinical - Cell culture Actionable In a preclinical study, treatment with IWR-1 decreased active beta-catenin levels and reduced growth of a colorectal cancer cell line harboring APC S811* in culture (PMID: 28179481). 28179481
APC S1197* APC S1278* colorectal cancer sensitive IWR-1 Preclinical - Cell culture Actionable In a preclinical study, treatment with IWR-1 decreased active beta-catenin levels and Tcf/LEF activity, and reduced growth of a colorectal cancer cell line harboring APC S1197* and APC S1278* in culture (PMID: 28179481). 28179481
APC E853* APC T1556fs colorectal cancer resistant IWR-1 Preclinical - Cell culture Actionable In a preclinical study, a colorectal cancer cell line harboring APC E853* and APC T1556fs (reported as APC T1556fs*3) demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with IWR-1 in culture (PMID: 28179481). 28179481
APC L665* APC R1450* colorectal cancer sensitive IWR-1 Preclinical - Cell culture Actionable In a preclinical study, a colorectal cancer cell line harboring APC L665* and APC R1450* demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with IWR-1 in culture (PMID: 28179481). 28179481
APC N1819fs colorectal cancer resistant IWR-1 Preclinical - Cell culture Actionable In a preclinical study, a colorectal cancer cell line harboring APC N1819fs (reported as N1819fs*7) and a wild-type copy of APC demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with IWR-1 in culture (PMID: 28179481). 28179481
APC S811* colorectal cancer sensitive XAV939 Preclinical - Cell culture Actionable In a preclinical study, XAV939 inhibited growth of a colorectal cancer cell line harboring APC S811* in culture (PMID: 28179481). 28179481
APC S1197* APC S1278* colorectal cancer sensitive XAV939 Preclinical - Cell culture Actionable In a preclinical study, XAV939 inhibited growth of a colorectal cancer cell line harboring APC S1197* and APC S1278* in culture (PMID: 28179481). 28179481
APC N1819fs APC wild-type colorectal cancer resistant XAV939 Preclinical - Cell culture Actionable In a preclinical study, a colorectal cancer cell line harboring APC N1819fs (reported as N1819fs*7) and a wild-type copy of APC demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with XAV939 in culture (PMID: 28179481). 28179481
APC L665* APC R1450* colorectal cancer sensitive XAV939 Preclinical - Cell culture Actionable In a preclinical study, a colorectal cancer cell line harboring APC L665* and APC R1450* demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with XAV939 in culture (PMID: 28179481). 28179481
APC E853* APC T1556fs colorectal cancer resistant XAV939 Preclinical - Cell culture Actionable In a preclinical study, a colorectal cancer cell line harboring APC E853* and APC T1556fs (reported as APC T1556fs*3) demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with XAV939 in culture (PMID: 28179481). 28179481
APC R216* colorectal cancer sensitive G007-LK Preclinical - Cell culture Actionable In a preclinical study, a patient-derived colorectal cancer cell line harboring APC R216* demonstrated sensitivity to G007-LK in culture (PMID: 28179481). 28179481
APC R216* colorectal cancer sensitive IWR-1 Preclinical - Cell culture Actionable In a preclinical study, IWR-1 inhibited growth of a patient-derived colorectal cancer cell line harboring APC R216* in culture (PMID: 28179481). 28179481
APC I1164fs colorectal cancer sensitive G007-LK Preclinical - Patient cell culture Actionable In a preclinical study, G007-LK inhibited growth of a patient-derived colorectal cancer cell line harboring APC I1164fs in culture (PMID: 28179481). 28179481
APC I1164fs colorectal cancer sensitive IWR-1 Preclinical - Cell culture Actionable In a preclinical study, IWR-1 inhibited growth of a patient-derived colorectal cancer cell line harboring APC I1164fs in culture (PMID: 28179481). 28179481
APC W553* colorectal cancer sensitive IWR-1 Preclinical - Cell culture Actionable In a preclinical study, IWR-1 inhibited growth of a patient-derived colorectal cancer cell line harboring APC W553* in culture (PMID: 28179481). 28179481
APC W553* colorectal cancer sensitive G007-LK Preclinical - Cell culture Actionable In a preclinical study, G007-LK inhibited growth of a patient-derived colorectal cancer cell line harboring APC W553* in culture (PMID: 28179481). 28179481
APC mutant medulloblastoma not applicable N/A Guideline Prognostic WNT-driven medulloblastomas, characterized by CTNNB1 or APC mutations, are associated with favorable prognosis (NCCN.org). detail...
APC mutant colon adenoma predicted - sensitive TetMYB Preclinical Actionable In a preclinical study, TetMYB treatment resulted in improved median survival compared to control (356 vs 183 days) in APC-driven mouse models of colon adenoma (Gastroenterology, Volume 154, Issue 6, Supplement 1, May 2018, Pages S-1269). detail...
APC inact mut prostate cancer decreased response Abiraterone Clinical Study Actionable In a clinical study, metastatic castrate-resistant prostate cancer patients harboring a Wnt pathway activating alteration demonstrated shorter median overall survival (23.6 mo vs 27.7 mo) and median time to PSA progression (6.5 mo vs 9.6 mo) following Zytiga (abiraterone) or Xtandi (enzalutamide) treatment compared to patients without Wnt pathway alterations, and APC or RNF43 inactivating mutations were independently associated with increased hazard of PSA progression (aHR 1.83; p=0.004) (PMID: 31176623). 31176623
APC inact mut prostate cancer decreased response Enzalutamide Clinical Study Actionable In a clinical study, metastatic castrate-resistant prostate cancer patients harboring a Wnt pathway activating alteration demonstrated shorter median overall survival (23.6 mo vs 27.7 mo) and median time to PSA progression (6.5 mo vs 9.6 mo) following Zytiga (abiraterone) or Xtandi (enzalutamide) treatment compared to patients without Wnt pathway alterations, and APC or RNF43 inactivating mutations were independently associated with increased hazard of PSA progression (aHR 1.83; p=0.004) (PMID: 31176623). 31176623
APC dec exp colorectal cancer predicted - sensitive G007-LK Preclinical Actionable In a preclinical study, G007-LK treatment altered gene expression pattern and induced growth arrest in intestinal organoids established from mouse models of colorectal cancer driven by APC knockdown, decreased proliferation and promoted differentiation in APC knockdown mouse models (PMID: 31337618). 31337618
APC L852* colorectal cancer predicted - resistant G007-LK Preclinical Actionable In a preclinical study, G007-LK treatment did not alter gene expression pattern or affect growth in intestinal organoids established from mouse models of colorectal cancer driven by APC L850* (corresponding to L852* in human), and had no effect on tumor cell growth and differentiation in APC L850* mouse models (PMID: 31337618). 31337618
APC Q886* colorectal cancer conflicting G007-LK Preclinical - Patient cell culture Actionable In a preclinical study, G007-LK inhibited viability of a patient-derived colorectal cancer cell line harboring APC Q886* in culture (PMID: 37968472). 37968472
APC Q886* colorectal cancer conflicting G007-LK Preclinical Actionable In a preclinical study, G007-LK treatment did not alter gene expression pattern or affect growth in mouse intestinal organoids expressing APC Q884* (corresponding to Q886* in human) in culture (PMID: 31337618). 31337618
APC Q1406* colorectal cancer predicted - sensitive G007-LK Preclinical Actionable In a preclinical study, G007-LK treatment altered gene expression pattern and inhibited growth of mouse intestinal organoids expressing APC Q1045* (corresponding to Q1046* in human) in culture (PMID: 31337618). 31337618
APC E582fs colorectal cancer predicted - resistant G007-LK Preclinical Actionable In a preclinical study, G007-LK treatment did not inhibit growth of mouse intestinal organoids expressing APC E580fs (corresponding to E582fs in human) in culture (PMID: 31337618). 31337618
APC Q886* colorectal cancer predicted - resistant XAV939 Preclinical Actionable In a preclinical study, XAV939 treatment did not affect growth of mouse intestinal organoids expressing APC Q884* (corresponding to Q886* in human) in culture (PMID: 31337618). 31337618
APC Q1406* colorectal cancer predicted - sensitive XAV939 Preclinical Actionable In a preclinical study, XAV939 treatment inhibited growth of mouse intestinal organoids expressing APC Q1045* (corresponding to Q1046* in human) in culture (PMID: 31337618). 31337618
APC Q1406* colorectal cancer predicted - sensitive NVP-TNKS656 Preclinical Actionable In a preclinical study, NVP-TNKS656 treatment inhibited growth of mouse intestinal organoids expressing APC Q1045* (corresponding to Q1046* in human) in culture (PMID: 31337618). 31337618
APC Q886* colorectal cancer predicted - resistant NVP-TNKS656 Preclinical Actionable In a preclinical study, NVP-TNKS656 treatment did not affect growth of mouse intestinal organoids expressing APC Q884* (corresponding to Q886* in human) in culture (PMID: 31337618). 31337618
APC mutant small intestine adenocarcinoma not applicable N/A Guideline Risk Factor Familial adenomatous polyposis results from germline mutations in the APC gene, and is associated with increased risk of developing small bowel adenocarcinoma (NCCN.org). detail...
APC mutant desmoid tumor not applicable N/A Guideline Diagnostic APC mutations aid the diagnosis of desmoid tumor (NCCN.org). detail...
APC inact mut desmoid tumor predicted - sensitive BMS-906024 Case Reports/Case Series Actionable In a clinical case study, BMS-906024 treatment resulted in a partial response that lasted for at least 2.6 years in a patient with a desmoid tumor harboring an inactivating APC mutation (PMID: 34590610). 34590610
APC T1556Nfs*3 desmoid tumor predicted - sensitive Celecoxib + Nirogacestat Case Reports/Case Series Actionable In a clinical case study, addition of Ogsiveo (nirogacestat) to Celecoxib treatment resulted in a reduction in tumor size and stable disease that was ongoing for at least 17 months in a pediatric patient with a desmoid tumor harboring APC T1556Nfs*3 (PMID: 32762028). 32762028
APC inact mut desmoid tumor predicted - sensitive Nirogacestat Case Reports/Case Series Actionable In a clinical case study, Ogsiveo (nirogacestat) resulted in stable disease lasting 9 months in a patient with a patient with a desmoid tumor harboring an inactivating APC mutation (PMID: 32762028). 32762028
APC R1450* APC LOH desmoid tumor predicted - sensitive Nirogacestat Case Reports/Case Series Actionable In a clinical case study, Ogsiveo (nirogacestat) resulted in tumor regression in a pediatric patient with a desmoid tumor harboring APC R1450* and loss of the APC heterozygosity who stayed on treatment for 6 months (PMID: 32762028). 32762028
APC S811* colorectal cancer sensitive STP1002 Preclinical - Cell line xenograft Actionable In a preclinical study, STP1002 inhibited Wnt/beta-catenin signaling and colony formation in colorectal cancer cell lines harboring APC S811* in culture and inhibited tumor growth in a cell line xenograft model (PMID: 35849876). 35849876
APC E1309Dfs*4 colorectal cancer sensitive STP1002 Preclinical - Cell culture Actionable In a preclinical study, STP1002 inhibited Wnt/beta-catenin signaling and colony formation in a colorectal cancer cell line harboring APC E1309Dfs*4 in culture (PMID: 35849876). 35849876
APC Q1338* colorectal cancer sensitive STP1002 Preclinical - Cell culture Actionable In a preclinical study, STP1002 inhibited Wnt/beta-catenin signaling and colony formation in colorectal cancer cell lines harboring APC Q1338* in culture (PMID: 35849876). 35849876
APC R1450* colorectal cancer sensitive STP1002 Preclinical - Pdx Actionable In a preclinical study, STP1002 inhibited tumor growth in a colorectal cancer patient-derived xenograft (PDX) model harboring APC R1450* (PMID: 35849876). 35849876
APC E853* APC T1556Nfs*3 colorectal cancer sensitive STP1002 Preclinical - Cell culture Actionable In a preclinical study, STP1002 inhibited Wnt/beta-catenin signaling and colony formation in a colorectal cancer cell line harboring APC E853* and APC T1556Nfs*3 in culture (PMID: 35849876). 35849876
APC S1356* colorectal cancer sensitive G007-LK Preclinical - Patient cell culture Actionable In a preclinical study, G007-LK inhibited viability of a patient-derived colorectal cancer cell line harboring APC S1356* in culture (PMID: 37968472). 37968472
APC Q1367* colorectal cancer resistant G007-LK Preclinical - Patient cell culture Actionable In a preclinical study, a patient-derived colorectal cancer cell line harboring APC Q1367* was resistant to G007-LK treatment, as demonstrated by failure to inhibit viability in culture (PMID: 37968472). 37968472
APC R499* colorectal cancer sensitive G007-LK Preclinical - Patient cell culture Actionable In a preclinical study, G007-LK inhibited viability of a patient-derived colorectal cancer cell line harboring APC R499* in culture (PMID: 37968472). 37968472
APC R876* colorectal cancer sensitive G007-LK Preclinical - Patient cell culture Actionable In a preclinical study, G007-LK inhibited viability of a patient-derived colorectal cancer cell line harboring APC R876* in culture (PMID: 37968472). 37968472
APC Q1378* colorectal cancer sensitive G007-LK Preclinical - Patient cell culture Actionable In a preclinical study, G007-LK inhibited viability of a patient-derived colorectal cancer cell line harboring APC Q1378* in culture (PMID: 37968472). 37968472
APC L1489* colorectal cancer sensitive G007-LK Preclinical - Cell culture Actionable In a preclinical study, G007-LK inhibited viability of a patient-derived colorectal cancer cell line harboring APC L1489* in culture (PMID: 37968472). 37968472
APC L954* colorectal cancer sensitive G007-LK Preclinical - Cell culture Actionable In a preclinical study, G007-LK inhibited viability of a patient-derived colorectal cancer cell line harboring APC L954* in culture (PMID: 37968472). 37968472
APC I1287Rfs*3 colorectal cancer sensitive G007-LK Preclinical - Cell culture Actionable In a preclinical study, G007-LK inhibited viability of a patient-derived colorectal cancer cell line harboring APC I1287Rfs*3 in culture (PMID: 37968472). 37968472
APC L1302Rfs*3 colorectal cancer resistant G007-LK Preclinical - Cell culture Actionable In a preclinical study, a patient-derived colorectal cancer cell line harboring APC L1302Rfs*3 was resistant to G007-LK treatment, as demonstrated by failure to inhibit viability in culture (PMID: 37968472). 37968472
APC G1116Efs*6 colorectal cancer sensitive G007-LK Preclinical - Cell culture Actionable In a preclinical study, G007-LK inhibited viability of a patient-derived colorectal cancer cell line harboring APC G1116Efs*6 in culture (PMID: 37968472). 37968472
APC K670* colorectal cancer sensitive G007-LK Preclinical - Cell culture Actionable In a preclinical study, G007-LK inhibited viability of a patient-derived colorectal cancer cell line harboring APC K670* in culture (PMID: 37968472). 37968472
APC Y935* APC L1489Yfs*18 colorectal cancer sensitive G007-LK Preclinical - Cell culture Actionable In a preclinical study, G007-LK inhibited viability of a patient-derived colorectal cancer cell line harboring APC L1489Yfs*18 and Y935* in culture (PMID: 37968472). 37968472
APC S1421Rfs*52 colorectal cancer sensitive G007-LK Preclinical - Cell culture Actionable In a preclinical study, G007-LK inhibited viability of a patient-derived colorectal cancer cell line harboring APC S1421Rfs*52 in culture (PMID: 37968472). 37968472
APC L665Ifs*8 APC R1450* colorectal cancer resistant G007-LK Preclinical - Cell culture Actionable In a preclinical study, a patient-derived colorectal cancer cell line harboring APC L665Ifs*8 and R1450* was resistant to G007-LK treatment, as demonstrated by failure to inhibit viability in culture (PMID: 37968472). 37968472
APC E633* APC E1494* APC Q1529* colorectal cancer sensitive G007-LK Preclinical - Cell culture Actionable In a preclinical study, G007-LK inhibited viability of a patient-derived colorectal cancer cell line harboring APC E1494*, E633*, and Q1529* in culture (PMID: 37968472). 37968472
APC S299Tfs*7 APC R805* colorectal cancer sensitive G007-LK Preclinical - Cell culture Actionable In a preclinical study, G007-LK inhibited viability of a patient-derived colorectal cancer cell line harboring APC R805* and S299Tfs*7 in culture (PMID: 37968472). 37968472
APC V830Gfs*12 APC T1556Nfs*3 colorectal cancer resistant G007-LK Preclinical - Cell culture Actionable In a preclinical study, a patient-derived colorectal cancer cell line harboring APC V830Gfs*12 and T1556Nfs*3, along with PIK3CA E542K, was resistant to G007-LK treatment, as demonstrated by failure to inhibit viability in culture (PMID: 37968472). 37968472
APC S1465Wfs*3 APC T1556Nfs*3 colorectal cancer sensitive G007-LK Preclinical - Cell culture Actionable In a preclinical study, G007-LK inhibited viability of a patient-derived colorectal cancer cell line harboring APC S1465Wfs*3 and T1556Nfs*3 in culture (PMID: 37968472). 37968472
APC R499* APC E1295* colorectal cancer sensitive G007-LK Preclinical - Cell culture Actionable In a preclinical study, G007-LK inhibited viability of a patient-derived colorectal cancer cell line harboring APC E1295* and R499* in culture (PMID: 37968472). 37968472
APC R216* colorectal cancer sensitive G007-LK + Trametinib Preclinical - Cell culture Actionable In a preclinical study, the addition of G007-LK to Mekinist (trametinib) treatment resulted in increased inhibition of viability compared to Mekinist (trametinib) alone in a colorectal cancer patient-derived cell line harboring APC R216* in culture (PMID: 37968472). 37968472
APC R302* APC E1345* colorectal cancer sensitive G007-LK + Trametinib Preclinical - Cell culture Actionable In a preclinical study, the addition of G007-LK to Mekinist (trametinib) treatment resulted in increased inhibition of viability compared to Mekinist (trametinib) alone in a colorectal cancer patient-derived cell line harboring APC R302* and E1345* in culture (PMID: 37968472). 37968472
APC E941* APC T1459fs colorectal cancer sensitive G007-LK + Trametinib Preclinical - Cell culture Actionable In a preclinical study, the addition of G007-LK to Mekinist (trametinib) treatment resulted in increased inhibition of viability compared to Mekinist (trametinib) alone in a colorectal cancer patient-derived cell line harboring APC E941* and T1459fs in culture (PMID: 37968472). 37968472
APC R876* colorectal cancer sensitive Buparlisib + G007-LK Preclinical - Cell culture Actionable In a preclinical study, the combination of G007-LK and Buparlisib (BKM120) inhibited viability of a colorectal cancer patient-derived cell line harboring APC R876* in culture (PMID: 37968472). 37968472